On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the clinical or regulatory workload. It’s a fresh entry point into one of pharma’s biggest growth categories, arriving on top of a quarter that already showed MannKind’s core business picking up speed.
A New Shot At Weight Loss
Rose Pharma isn’t starting from zero. ROSE-010 has already completed four human clinical trials, including a Phase 2a study in weight management that showed reductions in mealtime caloric intake and weight loss with a favorable gastrointestinal tolerability profile tied to its short exposure window. A separate Phase 2a trial in irritable bowel syndrome produced clinically meaningful, statistically significant pain relief, positioning the drug as a potential first targeted, on-demand therapy for acute IBS pain. For MannKind, that means the Technosphere platform is being licensed into a program that already has human data behind it.
The structure also limits MannKind’s downside. Rose Pharma keeps responsibility for clinical development, regulatory strategy, and commercialization, while MannKind’s role is development and manufacturing support only through completion of a Phase 1b study. In exchange, MannKind gets an equity interest, potential royalties, and board representation, exposure to a large market without taking on the balance sheet risk of running the trials itself. A recent patient preference survey of more than 1,300 adults with obesity found strong interest in a rapid-acting, short-duration GLP-1 profile, with results set to be presented at ObesityWeek 2026.
The timing helps too. On August 5, MannKind reported second-quarter revenue of $109.4 million, up 43% from the same period in 2025, alongside three catalysts achieved in a single year: FDA approval of a pediatric indication for Afrezza on May 29, approval of the Furoscix ReadyFlow autoinjector on July 23, and positive Phase 1b data for its nintedanib DPI program in idiopathic pulmonary fibrosis patients. Early uptake looks encouraging, with one in three of the top 100 pediatric insulin writers already prescribing Afrezza and Furoscix nephrology units dispensed climbing 67% over the first quarter.
Profits Vanish As Costs Climb
The Rose Pharma agreement is light on detail. MannKind did not disclose the specific financial terms, and the program is only advancing toward a Phase 1b study, years from any approval or royalty stream. Because Rose Pharma keeps control of clinical development, regulatory filings, and commercialization, MannKind’s upside depends on another company executing well in a crowded field.
The rest of the business tells a tougher story. MannKind swung to a net loss of $19 million in the second quarter of 2026, compared with net income of $668,000 a year earlier, and its six-month net loss reached $35.7 million versus $13.8 million in profit over the same stretch of 2025. Selling, general and administrative expenses jumped 84% year over year to $58.3 million, driven largely by the cost of promoting Furoscix and expanding the sales force behind the year’s approvals.
Cash also tightened. MannKind’s cash and cash equivalents fell to $52.9 million as of June 30, from $74.9 million at the end of 2025, and on July 24, the company closed a $50 million private placement specifically to fund a $45 million contingent payment triggered by the Furoscix ReadyFlow approval. Total stockholders’ deficit widened to $67.2 million from $51 million over the same period, a reminder that this year’s approvals have come with a real cash cost.
Wall Street Reads Mixed Signals
Hedge fund ownership of MannKind rose from 25 funds to 27 in the most recent quarter, pointing to institutions adding rather than trimming positions. Short interest sits at 8.37% of float, reflecting a real bear camp without outright pessimism. The stock trades at a forward price-to-earnings ratio of 28.90 as of September 15, pricing in meaningful future growth. That mix leaves sentiment and fundamentals not fully aligned.
The Long Runway Ahead
MannKind now has two stories running at once: a commercial business with real revenue growth and a string of approvals through 2026, and a pipeline bet on inhaled weight loss therapy that won’t produce clinical readouts for a while. For the collaboration to matter to MannKind’s results, ROSE-010 will need to clear Phase 1b and beyond under Rose Pharma’s direction, with MannKind mostly watching as an equity holder. For the near-term financials to improve, the spending behind Furoscix and the pediatric Afrezza launch will need to convert into sales growth that outpaces the cash MannKind is burning.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center